PledPharma Seeks Partner For Lead Therapy
Executive Summary
Jacques Näsström, CEO of Pled Pharma, chats with Sten Stovall, senior editor at Pharma Insights, about the company’s current hunt for licensing partners for lead product PledOx (calmangafodipir), which is being developed as a preventative therapy against nerve damage associated with cytotoxic therapy in colorectal cancer patients.